Physician profile
Sharon Burke
NPI 1043285844
$1,554.28
in general payments reported to CMS, 2019-2025
15 companies · $77.75 in 2025
The $77.75 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.56 · 2020: $181 · 2021: $194 · 2022: $290 · 2023: $274 · 2024: $483 · 2025: $77.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $354.81 | 2020-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $198.08 | 2020-2021 | |
| Corium, LLC | $176.67 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $172.67 | 2024 | Qelbree |
| Merck Sharp & Dohme LLC | $167.63 | 2019-2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Abbvie INC. | $121.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $70.39 | 2024 | |
| Collegium Pharmaceutical, INC. | $64.09 | 2025 | Jornay Pm |
| Tris Pharma INC | $52.31 | 2019-2023 | Dyanavel Xr |
| Aytu Biopharma, INC. | $42.89 | 2022-2025 | Karbinal |
| Neos Therapeutics, LP | $39.05 | 2021-2022 | |
| Sanofi Pasteur INC. | $35.31 | 2024 | |
| Masimo Corporation | $31.05 | 2024 | Set and Rainbow Set |
| Verrica Pharmaceuticals INC. | $16.10 | 2024 | Ycanth |
| Sobi, INC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.